Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
KZIA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: April 20, 2026
Report Source: 2026 2nd Quarter Report
Kazia Therapeutics Ltd. Stock Analysis KZIA
United States Health Care Micro Cap Report: Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Read More Kazia Therapeutics Ltd (KZIA) Chart
Key Statistics of Kazia Therapeutics Ltd (KZIA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$13.83Volume
168.24KP/E Ratio (TTM)
-52 Week Range
Market Cap
147.03MAvg. Volume
200.27KDividend Yield
-Financial Metrics & Statements of Kazia Therapeutics Ltd (KZIA)
FAQ's for Kazia Therapeutics Ltd (KZIA)
- According to Musaffa’s Shariah screening methodology, Kazia Therapeutics Ltd (KZIA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kazia Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kazia Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kazia Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kazia Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kazia Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.